Biscarbene gold(i) complexes: structure-activity-relationships regarding antibacterial effects, cytotoxicity, TrxR inhibition and cellular bioavailability.

A series of gold(i) complexes with two N-heterocyclic carbene ligands (biscarbene gold complexes) were prepared and evaluated for their effects against cancer cells and pathogenic bacteria. Proliferation inhibition was observed in cancer cells and in Gram-positive bacteria, whereas Gram-negative bacteria were less sensitive towards the compounds. The protein binding and cellular uptake were quantified and the combined results indicated a strong correlation between cellular bioavailability and antiproliferative effects. The biscarbene gold complexes inhibited bacterial and mammalian TrxRs with low to moderate potency. However, based on the obtained structure-activity-relationships and the high cellular accumulation levels, TrxR inhibition can be considered as a relevant contributor to the cellular pharmacology of biscarbene gold(i) complexes.

[1]  B. Karge,et al.  Gold(I) NHC Complexes: Antiproliferative Activity, Cellular Uptake, Inhibition of Mammalian and Bacterial Thioredoxin Reductases, and Gram-Positive Directed Antibacterial Effects. , 2017, Chemistry.

[2]  D. Schuppan,et al.  Ferrocenyl-Coupled N-Heterocyclic Carbene Complexes of Gold(I): A Successful Approach to Multinuclear Anticancer Drugs. , 2016, Chemistry.

[3]  R. Gust,et al.  Update on metal N-heterocyclic carbene complexes as potential anti-tumor metallodrugs , 2016 .

[4]  A. Casini,et al.  Determinants for Tight and Selective Binding of a Medicinal Dicarbene Gold(I) Complex to a Telomeric DNA G-Quadruplex: a Joint ESI MS and XRD Investigation. , 2016, Angewandte Chemie.

[5]  M. Sanaú,et al.  Versatile synthesis of cationic N-heterocyclic carbene-gold(i) complexes containing a second ancillary ligand. Design of heterobimetallic ruthenium-gold anticancer agents. , 2016, Chemical communications.

[6]  C. Che,et al.  Chemical biology of anticancer gold(III) and gold(I) complexes. , 2015, Chemical Society reviews.

[7]  V. Lynch,et al.  Targeting antioxidant pathways with ferrocenylated N-heterocyclic carbene supported gold(i) complexes in A549 lung cancer cells , 2015, Chemical science.

[8]  M. H. Franz,et al.  N-heterocyclic carbenes (NHC) with 1,2,4-oxadiazole-substituents related to natural products: synthesis, structure and potential antitumor activity of some corresponding gold(I) and silver(I) complexes. , 2015, European journal of medicinal chemistry.

[9]  M. Balzi,et al.  Evidence that the antiproliferative effects of auranofin in Saccharomyces cerevisiae arise from inhibition of mitochondrial respiration. , 2015, The international journal of biochemistry & cell biology.

[10]  A. Casini,et al.  Gold(I) NHC-based homo- and heterobimetallic complexes: synthesis, characterization and evaluation as potential anticancer agents , 2015, JBIC Journal of Biological Inorganic Chemistry.

[11]  I. Ott,et al.  A novel aminotriazole-based NHC complex for the design of gold(I) anti-cancer agents: synthesis and biological evaluation , 2015 .

[12]  P. Schultz,et al.  Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis , 2015, Proceedings of the National Academy of Sciences.

[13]  S. Wölfl,et al.  A TrxR inhibiting gold(I) NHC complex induces apoptosis through ASK1-p38-MAPK signaling in pancreatic cancer cells , 2014, Molecular Cancer.

[14]  T. Muth,et al.  Auranofin and related heterometallic gold(I)-thiolates as potent inhibitors of methicillin-resistant Staphylococcus aureus bacterial strains. , 2014, Journal of inorganic biochemistry.

[15]  C. Che,et al.  A binuclear gold(I) complex with mixed bridging diphosphine and bis(N-heterocyclic carbene) ligands shows favorable thiol reactivity and inhibits tumor growth and angiogenesis in vivo. , 2014, Angewandte Chemie.

[16]  D. Schuppan,et al.  Gold(I) Biscarbene Complexes Derived from Vascular‐Disrupting Combretastatin A‐4 Address Different Targets and Show Antimetastatic Potential , 2014, ChemMedChem.

[17]  A. Casini,et al.  Cytotoxic Gold(I) N‐heterocyclic Carbene Complexes with Phosphane Ligands as Potent Enzyme Inhibitors , 2014, ChemMedChem.

[18]  L. Messori,et al.  Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections , 2014, BioMetals.

[19]  R. Rubbiani,et al.  Historical and biochemical aspects of a seventeenth century gold-based aurum vitae recipe , 2014, JBIC Journal of Biological Inorganic Chemistry.

[20]  M. Djuran,et al.  Gold complexes as antimicrobial agents: an overview of different biological activities in relation to the oxidation state of the gold ion and the ligand structure. , 2014, Dalton transactions.

[21]  J. Lazo,et al.  Auranofin is an apoptosis-simulating agent with in vitro and in vivo anti-leishmanial activity. , 2014, ACS chemical biology.

[22]  A. Casini,et al.  A golden future in medicinal inorganic chemistry: the promise of anticancer gold organometallic compounds. , 2014, Dalton transactions.

[23]  Benoît Bertrand,et al.  Caffeine-based gold(I) N-heterocyclic carbenes as possible anticancer agents: synthesis and biological properties. , 2014, Inorganic chemistry.

[24]  R. Rubbiani,et al.  TrxR inhibition and antiproliferative activities of structurally diverse gold N-heterocyclic carbene complexes , 2013 .

[25]  L. Engstrand,et al.  Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  Peter Gölitz,et al.  Cover Picture: Champagne and Fireworks: Angewandte Chemie Celebrates Its Birthday (Angew. Chem. Int. Ed. 1/2013) , 2013 .

[27]  M. Arkin,et al.  A high throughput drug screen for Entamoeba histolytica identifies a new lead and target , 2012, Nature Medicine.

[28]  R. Gust,et al.  Synthesis, characterization, and in vitro studies of bis[1,3-diethyl-4,5-diarylimidazol-2-ylidene]gold(I/III) complexes. , 2012, Journal of medicinal chemistry.

[29]  S. Wölfl,et al.  Comparative in vitro evaluation of N-heterocyclic carbene gold(I) complexes of the benzimidazolylidene type. , 2011, Journal of medicinal chemistry.

[30]  S. Wölfl,et al.  Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties. , 2010, Journal of medicinal chemistry.

[31]  I. Ott,et al.  Comparative studies on the cytotoxicity, cellular and nuclear uptake of a series of chloro gold(I) phosphine complexes , 2010 .

[32]  A. Miele,et al.  Inhibition of Schistosoma mansoni Thioredoxin-glutathione Reductase by Auranofin , 2009, The Journal of Biological Chemistry.

[33]  I. Ott.  On the medicinal chemistry of gold complexes as anticancer drugs , 2009 .

[34]  R. Levine,et al.  Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au–Se adduct , 2009, JBIC Journal of Biological Inorganic Chemistry.

[35]  James L. Hickey,et al.  Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols. , 2008, Journal of the American Chemical Society.

[36]  James L. Hickey,et al.  Cationic, linear Au(I) N-heterocyclic carbene complexes: synthesis, structure and anti-mitochondrial activity. , 2006, Dalton transactions.

[37]  J. Verweij,et al.  Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations , 1996, Cancer Chemotherapy and Pharmacology.

[38]  S. Crooke,et al.  Cellular association, intracellular distribution, and efflux of auranofin via sequential ligand exchange reactions. , 1986, Biochemical pharmacology.

[39]  T. Mueller,et al.  Gold(I)-NHC complexes of antitumoral diarylimidazoles: structures, cellular uptake routes and anticancer activities. , 2012, Journal of inorganic biochemistry.

[40]  H. Reile,et al.  Chemosensitivity of human MCF-7 breast cancer cells to diastereoisomeric diaqua(1,2-diphenylethylenediamine) platinum(II) sulfates and specific platinum accumulation , 2004, Cancer Chemotherapy and Pharmacology.

[41]  R. Gust,et al.  Stability and cellular studies of [rac-1,2-bis(4-fluorophenyl)- ethylenediamine][cyclobutane-1,1-dicarboxylato]platinum(II), a novel, highly active carboplatin derivative , 1998, Journal of Cancer Research and Clinical Oncology.